BiotechTube
Curovir

Curovir

Stockholm, Sweden· Est.
curovir.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Curovir is a virtual, pre-clinical biotech company targeting a first-in-class antiviral for enteroviruses, a large family of viruses with no approved therapeutics. Its lead candidate, CUR-N399, is a small molecule with a dual mechanism targeting host factor PI4KB, showing broad-spectrum activity against EVs and unexpectedly high potency against RSV. The company operates with a lean, virtual model, supported by founder capital and grants, and is positioning its programs for significant unmet needs in respiratory diseases and pandemic preparedness.

Infectious DiseaseRespiratoryAutoimmune

Technology Platform

Host-targeted antiviral small molecules inhibiting Phosphatidylinositol 4-kinase III beta (PI4KB) to disrupt viral replication organelle formation, providing broad-spectrum activity against enteroviruses and RSV.

Opportunities

Curovir has a first-mover opportunity to create the first approved therapeutic for enteroviruses, addressing a massive unmet need in chronic respiratory disease exacerbations and severe infections.
The unexpected high potency of its lead candidate, CUR-N399, against RSV opens a second, multi-billion dollar market with high demand for oral antiviral treatments.
The host-targeting mechanism also positions the asset as a potential pandemic preparedness countermeasure for outbreak EV strains.

Risk Factors

The company faces high pre-clinical scientific risk, as the host-targeting mechanism's safety and efficacy in humans are unproven.
Financially, it is reliant on founder capital and grants, with a need for significant future investment to reach clinical trials.
Commercially, defining a clear regulatory path and value proposition for a broad-spectrum drug across diverse EV indications is challenging.

Competitive Landscape

For enteroviruses, Curovir faces little direct competition as there are no approved therapies, though academic groups and some biotechs may be exploring similar mechanisms. In RSV, the landscape is crowded and rapidly evolving with recently approved vaccines and monoclonal antibodies from Pfizer, GSK, and AstraZeneca/Sanofi, though the market for a direct-acting oral antiviral remains open. Host-targeting antivirals represent a niche but growing competitive approach.

More companies in Small Molecule Drugs →More companies in Sweden →